SI-BONE, Inc. (SIBN)

Over the past six months, SI-BONE's stock has experienced a challenging period, trading near its 52-week lows and showing a significant decline from its 52-week high. The stock price has declined approximately 44% from its 52-week high, with persistent selling pressure. There has been notable insider selling by company executives. JPMorgan reduced its stake by 32.1% in Q3, while other major institutions increased their positions. Short interest in SIBN surged by 25.5% in March, reaching 8.5% of the float. Despite the selling pressure, the company reported strong financial results for Q4, Q3, Q2 and Q1 2025. In February 2026, the company received FDA 510(k) clearance for its new iFuse INTRA Ti™ implant and entered a strategic distribution agreement with Smith+Nephew. The company has benefited from significant reimbursement milestones, including NTAP status for iFuse TORQ TNT and TPT payment for iFuse Bedrock Granite. Medicare also increased site-of-care reimbursement by 17%, and CMS created a new Level 7 APC for certain outpatient spine procedures.

SI-BONE's products and services experience demand seasonality, with typical third-quarter industry seasonality and a generally slower Q3 in Europe. SI-BONE has historically outperformed this seasonality. The company anticipates that new product launches will significantly impact European growth in 2026, offsetting some seasonal slowness.

SI-BONE, Inc. is a medical device company specializing in procedural solutions for musculoskeletal disorders of the sacropelvic anatomy, operating within the Healthcare sector. It focuses on surgical and medical instrument manufacturing and is a global leader in technology for the surgical treatment of sacropelvic disorders. The company's primary product portfolio revolves around its proprietary minimally invasive surgical implant systems designed to fuse the sacroiliac (SI) joint and address related conditions. Key products include the iFuse Implant System, iFuse-3D, iFuse-TORQ, iFuse Bedrock Granite, iFuse TORQ TNT, and iFuse INTRA Ti.

SI-BONE, Inc. has a global presence, with its headquarters in Santa Clara, California, United States. It maintains offices in Europe, including Italy (European HQ), Germany, France, and the United Kingdom. The company markets its products through a direct sales force and third-party sales agents and resellers both in the U.S. and internationally.

SI-BONE maintains a strong brand reputation as a global leader in technology for surgical treatment of sacropelvic disorders. The company emphasizes its unique body of clinical evidence, which includes two randomized controlled trials and over 135 peer-reviewed publications. Over 140,000 iFuse procedures have been performed worldwide by thousands of trained surgeons. The company has highlighted its continued innovation with new product clearances and strategic partnerships, which generally contribute positively to its industry standing and reputation.

SI-BONE, Inc. is predominantly owned by institutional investors and mutual funds, which hold concentrated stakes. Major institutional shareholders include First Light Asset Management, LLC, BlackRock, Inc., and Vanguard Group Inc. Founders and directors also retain meaningful voting influence. Individual insiders hold approximately 3.28% of the shares, while the general public holds about 0.619%. The top five institutional shareholders control about 45% of the votes.